 |
 |
 |
 |
 |
 |
News from SGC
Posted on Thursday 19th of July 2012
Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.
Posted on Friday 1st of June 2012
TORONTO, June 4, 2012 – The Structural Genomics Consortium (SGC), a group of expert researchers in recombinant antibody technology from the Universities of Toronto and Chicago and an industry partner have entered into a pioneering public-private partnership to generate renewable recombinant antibodies for epigenetic targets.
Posted on Tuesday 10th of April 2012
Takeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster.
Posted on Wednesday 28th of September 2011
The international Structural Genomics Consortium (SGC) today announced $48.9 million in new funding has been attained
Posted on Wednesday 28th of September 2011
"Sleeping sickness", also known as human African trypanosomiasis, is responsible for approximately 30,000 deaths each year and 70 million people are at risk of infection, as estimated by the World Health Organization
Posted on Wednesday 28th of September 2011
Functional and localization experiments in mammalian cells have demonstrated that Mps1 is essential for the fidelity of the cell cycle and genomic stability.
Posted on Wednesday 28th of September 2011
Apicomplexan parasites are a diverse group of protozoan parasites, several of which cause important human and animal diseases, such as malaria, cryptosporidiosis and toxoplasmosis
Posted on Wednesday 28th of September 2011
SGC Oxford - Toxoplasmosis is a parasitic disease caused by the apicomplexan protozoa Toxoplasma gondii and can pose a significant threat to immunocompromised individuals, e.g. those undergoing organ transplantation or chemotherapy and HIV/AIDS patients, who cannot fight back the infection and are thus dependent on drugs to control the infection.
Posted on Wednesday 28th of September 2011
The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors – "chemical probes" – for proteins involved in epigenetic signaling. Pfizer and GlaxoSmithKline (GSK) are now members of this collaboration, launched in late 2008 with the aim to provide the community with high quality research reagents, free from restriction on use.
Posted on Wednesday 28th of September 2011
The SGC has been awarded more than 0.5 M Euro as part of a joint EU FP7 -Health grant: 'Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application "Affinomics", which encompasses 15 participant labs in eight different European countries for 5 years.
The Affinomics programme aims to leverage existing efforts in Europe to generate large-scale resources of validated protein-binding molecules ('binders') as affinity reagents for characterisation of the human proteome. These binders will be applied in comprehensive structural and functional analyses of protein expression, interactions and complexes.
Pages
